Mary E. Rinella

A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis

Stephen A. Harrison, Pierre Bédossa, Cynthia D. Guy et al. · New England Journal of Medicine · 2024 · 1.7K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Zobair M. Younossi, Vlad Ratziu, Rohit Loomba et al. · The Lancet · 2019 · 1.2K citations · Full text

Medicine, Internal Medicine, Pharmacology +8

Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis

Philip N. Newsome, Iris Kliers, Laura Østergaard et al. · New England Journal of Medicine · 2025 · 690 citations

Medicine, Pharmacology, Pharmacotherapy +17

Semaglutide 2.4 mg in Participants With Metabolic Dysfunction‐Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 <scp>ESSENCE</scp> Trial

Philip N. Newsome, Arun J. Sanyal, Kristiane A. Engebretsen et al. · Alimentary Pharmacology & Therapeutics · 2024 · 123 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Call to action—Pediatric MASLD requires immediate attention to curb health crisis

Phillipp Hartmann, Marialena Mouzaki, Sara Hassan et al. · Hepatology · 2025 · 12 citations · Full text

Medicine, Child Health, Pediatrics +17